Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer-related mortality, with a five year survival less than 5%. The overwhelming majority of patients succumb to metastatic disease or tumor recurrence following apparently curative resection. Current treatment efforts in PDAC are focused almost entirely on reduction in "bulk" tumor size, rather than elimination of cells with tumor initiating and metastatic abilities. Research performed in our laboratory over the last funding cycle has identified a putative cancer stem cell (CSC) compartment in PDAC, delineated by high levels of expression of the enzyme aldehyde dehydrogenase. This minor subpopulation of ALDH "bright" cells is capable of self-renewal and tumor initiation, and is observed in elevated numbers in PDAC metastases. The ALDH "bright" cells are exquisitely dependent upon sustained Hedgehog (Hh) and Notch signals for their viability. Preferential elimination of the ALDH "bright" cells with small molecule Hh antagonists blocks systemic metastases and increases survival in PDAC preclinical models;conversely, gemcitabine enhances the relative proportion of ALDH "bright" cells, underscoring the pitfall of conventional anti-metabolite therapy. The current proposal will build upon these themes, by developing therapies that target the cellular compartment responsible for disease progression.
In Aim 1, we propose the first Phase II clinical trial of an orally bioavailable Hh antagonist in combination with gemcitabine in patients with advanced PDAC, with the primary objective of improving overall survival.
In Aim 2, we will study the emerging contribution Hh-dependent stromal responses to PDAC disease initiation and progression, including stromal interactions with the epithelial CSC compartment, using a newly developed conditional mouse model of Hh ligand misexpression.
In Aim 3, we will initiate a comprehensive preclinical trial with an orally bioavailable inhibitor of Notch signaling in spontaneously metastatic orthotopic xenograft model of PDAC, as a prelude to future clinical application. We anticipate that developing parallel and complementary therapeutic approaches against two critical developmental signaling pathways that sustain CSC viability in PDAC provides an unprecedented opportunity for ameliorating the dismal prognosis of this malignancy.

Public Health Relevance

Pancreatic cancer is the fourth most common cause of death in the United States. The long-term objective of this proposal is to improve the dismal prognosis of pancreatic cancer by developing therapies that target metastatic disease and tumor recurrence, the two most important clinical parameters that determine survival. In order to address this objective, this proposal will conduct the first clinical trial of Hedgehog (Hh) antagonists in patients with advanced pancreatic cancer, explore the role of Hh-dependent epithelial stromal interactions in a new mouse model, and begin preclinical trials with a novel pharmacological inhibitor of the Notch pathway in preclinical models of pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA113669-08
Application #
8223175
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Thurin, Magdalena
Project Start
2005-04-01
Project End
2015-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
8
Fiscal Year
2012
Total Cost
$306,839
Indirect Cost
$119,742
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Agarwal, Jasmin R; Wang, Qiuju; Tanno, Toshihiko et al. (2014) Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma. Mol Cancer Ther 13:1873-81
Streppel, M M; Lata, S; DelaBastide, M et al. (2014) Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene 33:347-57
Nimmagadda, Sridhar; Pullambhatla, Mrudula; Lisok, Ala et al. (2014) Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochem Biophys Res Commun 443:635-40
Cowan, Robert W; Maitra, Anirban (2014) Genetic progression of pancreatic cancer. Cancer J 20:80-4
Yabuuchi, Shinichi; Pai, Shweta G; Campbell, Nathaniel R et al. (2013) Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335:41-51
Streppel, Mirte Mayke; Pai, Shweta; Campbell, Nathaniel R et al. (2013) MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 19:4067-78
Chenna, Venugopal; Hu, Chaoxin; Pramanik, Dipankar et al. (2012) A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther 11:165-73
Gupta, Sonal; Pramanik, Dipankar; Mukherjee, Radha et al. (2012) Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Clin Cancer Res 18:280-9
Dal Molin, Marco; Hong, Seung-Mo; Hebbar, Sachidanand et al. (2012) Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum Pathol 43:585-91
Gong, Zhenqiang; Matzke, Nichilos J; Ermentrout, Bard et al. (2012) Evolution of patterns on Conus shells. Proc Natl Acad Sci U S A 109:E234-41

Showing the most recent 10 out of 52 publications